Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - Targets for therapeutic intervention?

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 425-441

  Jöhrer, Karin ^a   Hofbauer, Sebastian W ^b   Zelle Rieser, Claudia ^a   Greil, Richard ^a,b   Hartmann, Tanja N ^b  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Chemokine receptors; CLL; Multiple myeloma; T cells; Tumor microenvironment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; AMG 487; BKT 140; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GELATINASE B; INTERLEUKIN 15; INTERLEUKIN 21; KRH 16336; KRH 3955; LENALIDOMIDE; MDX 1100; MITOXANTRONE; MOGAMULIZUMAB; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; PROTEIN BCL 6; RAPAMYCIN; RITUXIMAB; SORAFENIB; T 140; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTOMA; LYMPHOID ORGAN; METASTASIS INHIBITION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS;

ANIMALS; B-LYMPHOCYTES; CELL COMMUNICATION; CHEMOKINES; HUMANS; IMMUNOMODULATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MICE; MULTIPLE MYELOMA; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

MURINAE;

EID: 84858694504     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.664128     Document Type: Review

References (170)

1. Mellado M, Vila-Coro AJ, Martinez C, Rodriguez-Frade JM. Receptor dimerization: a key step in chemokine signaling. Cell Mol Biol (Noisy-le-grand) 2001;47:575-82
2. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-34 (Pubitemid 33707930)
3. Bennett LD, Fox JM, Signoret N. Mechanisms regulating chemokine receptor activity. Immunology 2011;134:246-56
4. Sharma M. Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit Rev Biotechnol 2010;30:1-22
5. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 2004;48:489-96 (Pubitemid 39360399)
6. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment sntrategies. Blood 2009;114:3367-75
7. Baekkevold ES, Yamanaka T, Palframan RT, et al. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T scell recruitment. J Exp Med 2001;193:1105-12
8. Ebisuno Y, Tanaka T, Kanemitsu N, et al. Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules. J Immunol 2003;171:1642-6 (Pubitemid 36966445)
9. Kanemitsu N, Ebisuno Y, Tanaka T, et al. CXCL13 is an arrest chemokine for B cells in high endothelial venules. Blood 2005;106:2613-18 (Pubitemid 41510731)
10. Okada T, Ngo VN, Ekland EH, et al. Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp Med 2002;196:65-75 (Pubitemid 34747312)
11. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189:451-60 (Pubitemid 29187367)
12. Nakano H, Mori S, Yonekawa H, et al. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on moouse chromosome 4. Blood 1998;91:2886-95 (Pubitemid 28227539)
13. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-102 (Pubitemid 129516279)
14. Cyster JG, Ansel KM, Reif K, et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 2000;176:181-93
15. Ohl L, Henning G, Krautwald S, et al. Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J Exp Med 2003;197:1199-204 (Pubitemid 36570075)
16. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33 (Pubitemid 29468627)
17. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997;156:111-26 (Pubitemid 27197197)
18. Reif K, Ekland EH, Ohl L, et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002;416:94-9 (Pubitemid 34215407)
19. Bystry RS, Aluvihare V, Welch KA, et al. B cells and professional APCs recruict regulatory T cells via CCL4. Nat Immunol 2001;2:1126-32 (Pubitemid 33130146)
20. Schaniel C, Pardali E, Sallusto F, et al. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J Exp Med 1998;188:451-63 (Pubitemid 28369135)
21. Krzysiek R, Lefevre EA, Zou W, et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1alpha (MIP-1 alpha) and MIP-1beta chemokine production in human B cells. J Immunol 199 9;162:4455-63 (Pubitemid 29314842)
22. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-63
23. Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. Curr Opin Immunol 2011;23:111-18
24. Ansel KM, McHeyzer-Williams LJ, Ngo VN, et al. In vivo-activated CD4 cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med 1999;190:11023-34 (Pubitemid 29496505)
25. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363-72 (Pubitemid 28188896)
26. Pelletier N, McHeyzer-Williams LJ, Wong KA, et al. Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol 2010;11:1110-18
27. Schaerli P, Willimann K, Lang AB, et al. CXC chemokine receptor 5 expressiondefines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553-62
28. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004;5:943-52 (Pubitemid 39276239)
29. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-39 (Pubitemid 24140411)
30. Okada T, Miller MJ, Parker I, et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005;3:e150
31. Hargreaves DC, Hyman PL, Lu TT, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001;194:45-56 (Pubitemid 32660436)
32. Nie Y, Waite J, Brewer F, et al. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med 2004;200:1145-56 (Pubitemid 39507054)
33. Hauser AE, Debes GF, Arce S, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during thetime course of a memory immune response. J Immunol 2002;169:1277-82 (Pubitemid 34809169)
34. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005;105:1614-21 (Pubitemid 40223682)
35. Muehlinghaus G, Cigliano L, Huehn S, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005;105:3965-71 (Pubitemid 40656144)
36. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/ CXCL12 binds to and signals through the orphan receptor RDC1 in lymphocytes. J Biol Chem 2005;280:35760-6
37. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13 (Pubitemid 44352240)
38. Hartmann TN, Grabovsky V, Pasvolsky R, et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008;84:1130-40
39. Rot A. Chemokine patterning by glycosaminoglycans and interceptors. Front Biosci 2010;15:645-60
40. Levoye A, Balabanian K, Baleux F, et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009;113:6085-93
41. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. tJ Immunol 2002;169:4213-21 (Pubitemid 35178192)
42. Tokoyoda K, Zehentmeier S, Hegazy AN, et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009;30:721-30
43. Di Rosa F, Santoni A. Memory T-cellcompetition for bone marrow seeding. Immunology 2003;108:296-304 (Pubitemid 36332387)
44. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005;174:1269-73
45. Parretta E, Cassese G, Barba P, et al. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005;174:7654-64 (Pubitemid 40806270)
46. Herndler-Brandstetter D, Landgraf K, Jenewein B, et al. Human bone marrow hosts polyfunctional memory CD4+ and CD8+ T cells with close contact to IL-15-producing cells. J Immunol 2011;186:6965-71
47. Feuerer M, Beckhove P, Mahnke Y, et al. Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. Int J Oncol 2004;25:867-76
48. Reichardt P, Dornbach B, Rong S, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007;110:1519-29 (Pubitemid 47443968)
49. Molon B, Gri G, Bettella M, et al. T cell costimulation by chemokine receptors. Nat Immunol 2005;6:465-71 (Pubitemid 41716759)
50. Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol 2006;27:421-7 (Pubitemid 44216192)
51. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-8 (Pubitemid 37363477)
52. Foucar K, Friedman K, Llewellyn A, et al. Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down's syndrome. Am J Clin Pathol 1992;97:584-90
53. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403-13 (Pubitemid 34546268)
54. Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006;55:210-20
55. Totterman TH, Carlsson M, Simonsson B, et al. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989;74:786-92 (Pubitemid 19208823)
56. Tinhofer I, Weiss L, Gassner F, et al. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 2009;32:302-9
57. Pinon Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011;25:1452-8
58. Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol 2011;166:154-63
59. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173-81
60. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37 (Pubitemid 351949771)
61. Durig J, Ebeling P, Grabellus F, et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007;67:8653-61 (Pubitemid 47437441)
62. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463-72
63. San Miguel JF, Gonzalez M, Gascon A, et al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1992;80:305-9
64. Kay NE, Leong T, Bone N, et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 1998;100:459-63 (Pubitemid 28270479)
65. Li Y, Chen S, Yang L, et al. Change in expression pattern of TCR-CD3 complex in patients with multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2011;16:143-50
66. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer 2006;106:1296-305 (Pubitemid 43363906)
67. Koike M, Sekigawa I, Okada M, et al. Relationship between CD4+/CD8+ T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 2002;26:705-11 (Pubitemid 34628368)
68. Massaia M, Bianchi A, Attisano C, et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Bl.ood 1991;78:1770-80
69. Dianzani U, Pileri A, Boccadoro M, et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988;72:1064-8
70. Tinhofer I, Marschitz I, Henn T, et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610-18 (Pubitemid 30041677)
71. Hilbert DM, Shen MY, Rapp UR, Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci USA 1995;92:649-53
72. Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 2004;45:2491-6 (Pubitemid 40081196)
73. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002;99:2977-84 (Pubitemid 34525388)
74. Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004;76:462-71 (Pubitemid 39006961)
75. Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc 2004;79:318-25 (Pubitemid 38269234)
76. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:3584-92
77. Redondo-Munoz J, Jose TM, Garcia-Marco JA, Garcia-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/ CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 2008;111:383-6
78. Chunsong H, Yuling H, Li W, et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006;177:6713-22 (Pubitemid 44715035)
79. Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-25 (Pubitemid 350106325)
80. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-8
81. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117:1662-9
82. Zucchetto A, Benedetti D, Tripodo C, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009;69:4001-9
83. Trentin L, Miorin M, Facco M, et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007;138:594-602 (Pubitemid 47206713)
84. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/ SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708-17 (Pubitemid 46482062)
85. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5 (Pubitemid 30463390)
86. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003;101:4998-5006 (Pubitemid 36857764)
87. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor- 1alpha modulates VLA-4 integrinmediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51 (Pubitemid 32060316)
88. Parmo-Cabanas M, Bartolome RA, Wright N, et al. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004;294:571-80 (Pubitemid 38326753)
89. Vanderkerken K, Vande Broek I, Eizirik DL, et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002;19:87-90 (Pubitemid 34208358)
90. Johrer K, Janke K, Krugmann J, et al. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004;10:1901-10 (Pubitemid 38375546)
91. Vande Broek I, Asosingh K, Vanderkerken K, et al. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62 (Pubitemid 36520872)
92. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000;95:627-32 (Pubitemid 30041679)
93. Ocana E, Delgado-Perez L, Campos-Caro A, et al. The prognostic role of CXCR3 expression by chroniclymphocytic leukemia B cells. Haematologica 2007;92:349-56 (Pubitemid 350143544)
94. Giuliani N, Bonomini S, Romagnani P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006;91:1489-97 (Pubitemid 44736115)
95. Pellegrino A, Antonaci F, Russo F, et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett 2004;207:221-7 (Pubitemid 38457044)
96. Foa R, Giovarelli M, Jemma C, et al. Interleukin 2 (IL 2) and interferon-gamma production by lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood 1985;66:614-19 (Pubitemid 15230766)
97. Gallego A, Vargas JA, Castejon R, et al. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL. Cytometry B Clin Cytom 2003;56:23-9 (Pubitemid 38292613)
98. Podhorecka M, Dmoszynska A, Rolinski J. Intracellular IFN-gamma expression by CD3+/CD8+ cell subset in B-CLL patients correlates with stage of the disease. Eur J Haematol 2004;73:29-35 (Pubitemid 38824187)
99. Kiaii S, Choudhury A, Mozaffari F, et al. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 2006;47:1229-38 (Pubitemid 44269628)
100. Buschle M, Campana D, Carding SR, et al. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-18 (Pubitemid 23008103)
101. Wilkinson PC, Islam LN. Recombinant IL-4 and IFN-gamma activate locomotor capacity in human B lymphocytes. Immunology 1989;67:237-43 (Pubitemid 19151478)
102. Rojas R, Roman J, Torres A, et al. Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage. Leukemia 1996;10:1782-8 (Pubitemid 26380025)
103. Zaki M, Douglas R, Patten N, et al. Disruption of the IFN-gamma cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis. Leuk Res 2000;24:611-21 (Pubitemid 30365112)
104. Jenh CH, Cox MA, Hipkin W, et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine 2001;15:113-21 (Pubitemid 34587493)
105. Calissano C, Damle RN, Marsilio S, et al. Intra-clonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/ quiescent cells. Mol Med 2011;published online 23 September 2011; doi:; 10.2119/molmed.2011.00360
106. Vlad A, Deglesne PA, Letestu R, et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009;69:6387-95
107. Quiroga MP, Burger JA. BCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res 2010;70:5194
108. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;107:53-63 (Pubitemid 32047414)
109. Haabeth OA, Lorvik KB, Hammarstrom C, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240
110. Luster AD, Leder P. IP-10, a -C-X-Cchemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65 (Pubitemid 23260444)
111. Li G, Tian L, Hou JM, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 2005;11:4217-24 (Pubitemid 40791588)
112. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 2005;206:68-75 (Pubitemid 40613436)
113. Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999;13:1954-9
114. Rehm A, Mensen A, Schradi K, et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011;118:1020-33
115. Hasegawa H, Nomura T, Kohno M, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 2000;95:30-8 (Pubitemid 30017221)
116. Hopken UE, Foss HD, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002;99:1109-16 (Pubitemid 34547061)
117. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6 (Pubitemid 32225831)
118. Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:3406-12 (Pubitemid 37082736)
119. Alfonso-Perez M, Lopez-Giral S, Quintana NE, et al. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 2006;79:1157-65 (Pubitemid 44835549)
120. Wiley HE, Gonzalez EB, Maki W, et al. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001;93:1638-43 (Pubitemid 33094871)
121. Panjideh H, Koch M, Oden F, et al. CXCR5-directed Immunotherapy of B cell Non-Hodgkin lymphoma and autoimmune disease. Int Immmunol Suppl 2010;22:v23
122. Wijtmans M, Verzijl D, Leurs R, et al. Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 2008;3:861-72
123. Cambien B, Karimdjee BF, Richard-Fiardo P, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 2009;100:1755-64
124. Walser TC, Rifat S, Ma X, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model ofmetastatic breast cancer. Cancer Res 2006;66:7701-7 (Pubitemid 44289229)
125. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009;8:23-33
126. Bristol-Myers Squibb. A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis. ClinicalTrials. gov NCT00295282. Available from: http://clinicaltrials.gov/ct2/show/ NCT00295282? term=NCT00295282&rank= 1
127. Bristol-Myers Squibb. A Study of MDX-1100 in Subjects With Active Ulcerative Colitis. ClinicalTrials.gov NCT00656890. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00656890? term=NCT00656890&rank=1
128. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-12 (Pubitemid 34602402)
129. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102 (Pubitemid 41095043)
130. Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 2010;16:695-700
131. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300 (Pubitemid 40389423)
132. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony- stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007;16:657-66 (Pubitemid 47378738)
133. Genzyme. Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ClinicalTrials.gov NCT00694590. Available from: http://clinicaltrials.gov/ ct2/show/NCT00694590? term=NCT00694590&rank=1
134. Duke University, Celgene Corp., Genzyme. Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov NCT01373229. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01373229? term=NCT01373229&rank=1
135. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90 (Pubitemid 36418178)
136. Murakami T, Kumakura S, Yamazaki T, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother 2009;53:2940-8
137. Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011;39:282-92
138. Biokine Therapeutics Ltd. Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients. ClinicalTrials.gov NCT01010880. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01010880? term=NCT01010880&rank=1
139. Liu Q, Chen T, Chen G, et al. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 2007;44:2686-96 (Pubitemid 46240316)
140. Villablanca EJ, Zhou D, Valentinis B, et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008;84:871-9
141. Satoh K, Fukumoto Y, Nakano M, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009;81:226-34
142. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009;4:e5263
143. Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004;172:85-93 (Pubitemid 38058605)
144. Damas JK, Boullier A, Waehre T, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25:2567-72 (Pubitemid 43732280)
145. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86 (Pubitemid 35332050)
146. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67
147. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90 (Pubitemid 38268973)
148. Huang MC, Greig NH, Luo W, et al. Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. Clin Immunol 2011;138:201-11
149. Xu Y, Li J, Ferguson GD, et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009;114:338-45
150. Oliveira AM, Maria DA, Metzger M, et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009;33:970-3
151. Lee ES, Kim YA, Kwon HJ, et al. Thalidomide upregulates macrophage inflammatory protein-1alpha in a herpes simplex virus-induced Behcet'a disease-like animal model. Arch Dermatol Res 2004;296:175-81 (Pubitemid 39371412)
152. Fuchida SI, Shimazaki C, Hirai H, et al. The effects of thalidomide on chemotactic migration of multiplemyeloma cell lines. Int J Lab Hematol 2008;30:220-9 (Pubitemid 351679515)
153. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2011;published online 6 August 2011; doi:S0190-9622(11)00124-1 [pii];10.1016/j.jaad.2011.01.015
154. Fehniger TA, Larson S, Trinkaus K, et al. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
155. Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011;11:355-63
156. Washington University School of Medicine. AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia. ClinicalTrials.gov NCT00512252. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00512252? term=NCT00512252&rank=1
157. Washington University School of Medicine. Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia. ClinicalTrials.gov NCT00906945. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00906945? term=NCT00906945&rank=1
158. M.D. Anderson Cancer Center, Bayer, Genzyme, Onyx Pharmaceuticals. Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations ClinicalTrials.gov NCT00943943. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00943943? term=NCT00943943&rank=1
159. Genzyme. Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia. ClinicalTrials.gov NCT00990054. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00990054? term=NCT00990054&rank=1
160. Washington University School of Medicine. IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML). ClinicalTrials.gov NCT01027923. Available from: http://clinicaltrials.gov/ ct2/show/NCT01027923? term=NCT01027923&rank=1
161. St. Jude Children's Research Hospital, Genzyme. A Pediatric Study of Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation. ClinicalTrials.gov NCT01068301. Available from: http:// clinicaltrials.gov/ct2/ show/ NCT01068301? term=NCT01068301&rank=1
162. M.D. Anderson Cancer Center, Genzyme. Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML). ClinicalTrials.gov NCT01160354. Available from: http:// clinicaltrials.gov/ct2/ show/ NCT01160354? term=NCT01160354&rank=1
163. Cardiff University, Leukaemia & Lymphoma Research Group, Experimental Cancer Medicine Centre Network. A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220 or the CXCR4 Inhibitor Plerixafor With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. ClinicalTrials.gov NCT01236144. Available from: http://clinicaltrials.gov/ ct2/show/NCT01236144? term=NCT01236144&rank=1
164. Emory University, Children's Healthcare of Atlanta, Pediatric Oncology Experimental Therapeutics Investigation Consortium POETIC Plerixafor as Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients. ClinicalTrials.gov NCT01319864. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01319864? term=NCT01319864&rank=1
165. Weill Medical College of Cornell University, Genzyme. Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML). ClinicalTrials.gov NCT01352650. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01352650? term=NCT01352650&rank=1
166. Kyowa Hakko Kirin Co., Ltd. Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemialymphoma. ClinicalTrials.gov NCT00920790. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00920790? term=NCT00920790&rank=1
167. Kyowa Hakko Kirin Co., Ltd. Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma. ClinicalTrials.gov NCT01192984. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01192984? term=NCT01192984&rank=1
168. Kyowa Hakko Kirin Co., Ltd. Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL. ClinicalTrials.gov NCT00355472. Available from: http://clinicaltrials.gov/ ct2/show/NCT00355472? term= NCT00355472&rank=1
169. Kyowa Hakko Kirin Co., Ltd. Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15. ClinicalTrials.gov NCT01173887. Available from: http://clinicaltrials.gov/ ct2/show/NCT01173887? term=NCT01173887&rank=1
170. Kyowa Hakko Kirin Pharma, Inc. Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001. ClinicalTrials.gov NCT01226472. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01226472? term=NCT01226472&rank=1